AUA 2012 - Abiraterone acetate (an androgen biosynthesis inhibitor) in patients with metastatic castration-resistant prostate cancer - Slide Presentation

ATLANTA, GA USA (UroToday) - Abiraterone acetate inhibits CYP17, an enzyme complex needed for androgen biosynthesis, and when used in combination with prednisone improved the overall survival in patients with mCRPC who received prior chemotherapy containing docetaxel.

zytiga slide 1

zytiga slide 2

zytiga slide 3

zytiga slide 4


Provided by Judd W. Moul, MD, FACS from his presentation at at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA



View full AUA Coverage